Epithelioid angiosarcoma is a rare, highly aggressive malignant tumor arising from vascular endothelial cells, characterized by epithelioid morphology—i.e., tumor cells that resemble epithelial cells in appearance but are of endothelial origin.
Key Features:
Histology: Large, pleomorphic epithelioid cells with abundant eosinophilic cytoplasm, prominent nucleoli, and frequent mitoses. Often displays areas of necrosis and hemorrhage.
Immunohistochemistry: Positive for CD31, ERG, FLI-1, and CD34; often negative for epithelial markers like cytokeratin (though focal positivity can occur, contributing to misdiagnosis).
Clinical Behavior: Extremely high rate of local recurrence and distant metastasis (lungs, liver, bone), with poor prognosis—median survival often less than 12 months.
Common Sites: Deep soft tissues (e.g., pelvis, limbs), skin, breast, pleura, bone, and rarely the spine or CNS.
Etiology: Sometimes associated with chronic lymphedema, prior radiation exposure, or foreign material (e.g., vascular grafts), though most cases are idiopathic.
Nan et al. 1) describe a rare case of epithelioid angiosarcoma (EA) involving the cervical spine, presenting with pathological fracture and kyphotic deformity, and document the surgical and adjuvant management as well as the clinical outcome in the World Journal of Clinical Cases.
The authors claim novelty by describing a rare anatomical presentation of EA. However, this degenerates into a predictable narrative with no new pathophysiological insights, no hypothesis generated, and no clinical paradigm challenged. It is the kind of “rare case” that proliferates in low-barrier journals precisely *because* it demands no intellectual risk.
The authors bypass the opportunity to deepen our understanding of the radiological-morphological signature of EA in the spine. No comparative imaging, no differential diagnostic flowchart, no histopathological discussion beyond standard CD31/CD34 immunostaining. If this case had been published in 1995, it would be equally uninformative.
Two major spine surgeries (posterior decompression + anterior corpectomy) followed by immediate radiotherapy in a moribund patient demonstrate therapeutic overreach without oncological strategy. There is no discussion on multidisciplinary planning, palliative thresholds, or whether delaying surgery or avoiding the second procedure might have prevented ARDS. The reader is left with the impression of a surgical reflex, not an evidence-based decision.
In a tumor type notorious for being misdiagnosed as metastasis, chordoma, or sarcoma NOS, the absence of a differential diagnostic framework or advanced markers (ERG, FLI1, HHV-8, etc.) is alarming. Histological laziness cloaked in “rare disease” rhetoric.
The patient dies 3 weeks after surgery, yet the discussion fails to draw any causal or cautionary link between the interventions and the fatal ARDS. No autopsy data, no postmortem imaging, no pulmonary workup. This omission sterilizes the clinical narrative, reducing it to anecdote.
The case implicitly raises an ethical dilemma—should maximal surgery be performed in aggressive, terminal tumors without demonstrated systemic control? Yet the authors shy away from even mentioning this, let alone framing it for academic discussion.
Published in a journal known for minimal peer review stringency, the article offers no citations of recent molecular or targeted therapy advances, no engagement with broader oncological guidelines, and no rationale for the treatment decisions beyond procedural listing.
This case report is an example of procedural reporting devoid of scientific merit, clinical reflection, or ethical introspection. It contributes nothing to the understanding of EA, its diagnosis, biology, or management—beyond reiterating its rarity. In its current form, it is neither hypothesis-generating nor practice-changing, and serves as a cautionary tale on how not to write a case report.